The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Retinitis Pigmentosa Market Between 2026 And 2030?
The retinitis pigmentosa market has experienced substantial growth recently. It is projected to expand from $12.15 billion in 2025 to reach $13.16 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. This historic growth can be attributed to an improved understanding of genetic retinal disorders, the expansion of diagnostic genetic testing, increased patient advocacy and awareness, the availability of vitamin-based supportive therapies, and the growth of ophthalmic research institutions.
The market for retinitis pigmentosa is anticipated to experience substantial expansion in the coming years. This market is projected to reach $18.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. Key factors contributing to this growth during the forecast period include greater investments in gene therapy development, an increasing need for treatments that modify the disease, broader adoption of personalized medicine strategies, enhanced incorporation of assistive vision technologies, and a heightened emphasis on early genetic detection. Significant trends observed during the forecast period involve a heightened interest in gene-based therapies, wider acceptance of retinal prosthetic devices, more frequent use of genetic testing for diagnostic purposes, the development of more comprehensive vision enhancement aids, and intensified research efforts into disease-modifying therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16528&type=smp
What Major Drivers Are Influencing Demand In The Retinitis Pigmentosa Market?
The retinitis pigmentosa market is anticipated to expand in the future, propelled by an increase in healthcare expenditure. Healthcare expenditure denotes the total financial outlay for medical goods and services, encompassing medical treatments, medications, hospitalizations, and preventive care, within a specified timeframe, reflecting the overall cost of healthcare provision for a population. This expenditure is on the rise due to the increasing expense of advanced medical technologies, the growth of aging populations, and the prevalence of chronic diseases. For retinitis pigmentosa, healthcare spending is particularly focused on advancing diagnostic methods, developing effective treatments, and providing supportive care to manage vision loss. For example, in April 2025, the American Medical Association (AMA), a professional association based in the U.S., reported that U.S. health spending surged by 7.5% in 2023, reaching $4.9 trillion, which averaged approximately $14,570 per person, marking a significant increase from the 4.6% growth rate observed in 2022. Consequently, the rising healthcare expenditure is a key factor driving the growth of the retinitis pigmentosa market.
Which Market Segments Are Examined In The Retinitis Pigmentosa Market Study?
The retinitis pigmentosa market covered in this report is segmented –
1) By Type: Autosomal Recessive, Autosomal Dominant, X-Linked
2) By Treatment: Vitamin A, Docosahexaenoic Acid (DHA), Calcium Channel Blockers, Gene Therapy, Retinal Eye Prosthetics, Other Treatments
3) By Diagnosis: Electroretinogram, Visual Field Testing, Genetic Testing, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users
Subsegments:
1) By Autosomal Recessive: Early-Onset Autosomal Recessive Retinitis Pigmentosa, Late-Onset Autosomal Recessive Retinitis Pigmentosa
2) By Autosomal Dominant: Early-Onset Autosomal Dominant Retinitis Pigmentosa, Late-Onset Autosomal Dominant Retinitis Pigmentosa
3) By X-Linked: X-Linked Recessive Retinitis Pigmentosa, X-Linked Dominant Retinitis Pigmentosa
What Key Developments And Trends Are Impacting The Retinitis Pigmentosa Market?
Companies operating within the retinitis pigmentosa market are increasingly concentrating on developing innovative treatment options, such as gene therapy, to provide more effective and targeted solutions for managing and potentially curing this debilitating condition. Gene therapy for retinitis pigmentosa (RP) involves the delivery of functional genes to replace or repair the defective ones causing the disease. This innovative treatment aims to restore normal function to the affected photoreceptor cells in the retina, thereby slowing or potentially halting the progression of vision loss. For instance, in April 2024, ViGeneron GmbH, a Germany-based biotechnology company, launched a Phase Ib clinical trial to evaluate the safety, tolerability, and efficacy of VG901, a gene therapy designed to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The trial is an open-label, single-arm, dose-escalation study that will investigate the intravitreal injection of VG901 in patients with autosomal recessive RP due to biallelic CNGA1 mutations.
Who Are The Primary Competitors In The Retinitis Pigmentosa Market?
Major companies operating in the retinitis pigmentosa market are Johnson And Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, Acucela Inc., AGTC Applied Genetic Technologies Corporation, ProQR Therapeutics NV, Nanoscope Therapeutics Inc, Beacon Therapeutics Ltd, Horama SA, ViGeneron GmbH
Read the full retinitis pigmentosa market report here:
https://www.thebusinessresearchcompany.com/report/retinitis-pigmentosa-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The Retinitis Pigmentosa Market?
North America was the largest region in the retinitis pigmentosa market in 2025. The regions covered in the retinitis pigmentosa market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Retinitis Pigmentosa Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=16528&type=smp
Browse Through More Reports Similar to the Global Retinitis Pigmentosa Market 2026, By The Business Research Company
Retinal Vein Occlusion Global Market Report
https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report
Chronic Venous Occlusions Treatment Global Market Report
Retinal Disorder Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model